About Plexium
Plexium is a company based in San Diego (United States) founded in 2017 by Andrew MacConnell. Plexium has raised $225.12 million across 5 funding rounds from investors including Citadel, RA Capital and SoftBank Vision Fund. The company has 81 employees as of December 31, 2021. Plexium offers products and services including TPD Platform, Monovalent Degraders, and Molecular Glues. Plexium operates in a competitive market with competitors including Accutar Biotechnology, Lycia Therapeutics, Vicinitas, Photys Therapeutics and Uvic Steratics, among others.
- Headquarter San Diego, United States
- Employees 81 as on 31 Dec, 2021
- Founders Andrew MacConnell
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Plexium, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$225.12 M (USD)
in 5 rounds
-
Latest Funding Round
$60.12 M (USD), Series B
Jul 14, 2025
-
Investors
Citadel
& 12 more
-
Employee Count
81
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Plexium
Plexium offers a comprehensive portfolio of products and services, including TPD Platform, Monovalent Degraders, and Molecular Glues.
Platform for discovering targeted protein degrader therapeutics
Drugs designed for rational protein degradation applications
Compounds that facilitate targeted protein interactions
People of Plexium
Unlock access to complete
Unlock access to complete
Funding Insights of Plexium
Plexium has successfully raised a total of $225.12M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $60.12 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Plexium
Plexium has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, RA Capital and SoftBank Vision Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
VC firm focusing on life science sector
|
Locked | Locked | Locked |
Investor details for Plexium
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Plexium
Investment portfolio details for Plexium
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Plexium
Detailed financials for Plexium
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Plexium Comparisons
Peer comparison for Plexium
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Plexium
Plexium operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accutar Biotechnology, Lycia Therapeutics, Vicinitas, Photys Therapeutics and Uvic Steratics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-assisted tools for drug discovery are developed.
|
|
| Locked | Locked | Locked |
Protein degradation drugs are developed for cancer and autoimmune diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for cancer and genetic disorders
|
|
| Locked | Locked | Locked |
Protein-based small molecules are developed to treat human diseases.
|
|
| Locked | Locked | Locked |
Anti-cancer drugs are developed via Proteolysis Targeting Chimera technology.
|
Detailed competitors of Plexium
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Plexium
Complete news archive for Plexium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Plexium
Plexium was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Plexium is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Plexium is a funded company, having raised a total of $225.12M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Plexium is 81.
Plexium offers integrated chemistry services. They provide synthetic organic chemistry, analytical chemistry, spectroscopy, combinatorial chemistry, and others.
Plexium's top competitors include Photys Therapeutics, Uvic Steratics and Accutar Biotechnology.
Plexium offers TPD Platform, Monovalent Degraders, and Molecular Glues.
Plexium has 13 investors. Key investors include Citadel, RA Capital, SoftBank Vision Fund, The Column Group, and TCG Crossover.